Iain D. Dukes

Iain D Dukes MA DPhil is a Venture Partner with OrbiMed Advisors LLC. Iain is Chairman of the Board of Iovance Biotherapeutics (NASDQ:IOVA) as well as KaNDy Therapeutics and serves as CEO of Arrys Therapeutics and Theseus Pharmaceuticals, respectively. Additionally, Iain is President of Kartos Therapeutics and sits on the Boards of Kyn Therapeutics, NeRRe Therapeutics and ENYO Pharma. Most recently Iain was a Senior Vice President, Business Development & Licensing Merck where he oversaw all licensing deals for Merck Research Laboratories, including external research, out-licensing, regional deals and academic alliances. Iain has more than 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership, as well as consulting for numerous biotech and venture capital organizations. Before joining Merck, he served as vice president of External Research and Development at Amgen. He has also held positions as president and CEO of Essentialis Therapeutics and as Vice President, Scientific and Technology Licensing at GlaxoSmithKline. Iain received his D.Phil. degree from the University of Oxford where he also received a B.A. in Jurisprudence.